Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor XIII in chronic inflammatory bowel diseases

R Lorenz1, P Olbert, P Born

  • 12nd Department of Internal Medicine, Klinikum Rechts der Isar, Technical University Munich, Germany.

Seminars in Thrombosis and Hemostasis
|January 1, 1996
PubMed
Summary

Factor XIII concentrate effectively treats ulcerative colitis by improving hemostasis and wound healing. This therapy significantly reduced bleeding and inflammation in patients with inflammatory bowel disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the association between BMI classes and the outcome in incisional hernia repair?

Hernia : the journal of hernias and abdominal wall surgery·2025
Same author

[Stones in the lower pole and their treatment].

Urologie (Heidelberg, Germany)·2025
Same author

Female athletes explicitly gesture in emotional situations.

Frontiers in psychology·2025
Same author

[Urinary diversion in old patients (80+ years)].

Urologie (Heidelberg, Germany)·2024
Same author

Is there a link between Spigelian and inguinal hernias? A case series.

Hernia : the journal of hernias and abdominal wall surgery·2024
Same author

Long-term evaluation of the Hernia Compact course of the German Hernia School.

Hernia : the journal of hernias and abdominal wall surgery·2024

Area of Science:

  • Gastroenterology
  • Hematology
  • Wound Healing

Background:

  • Inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), involves severe inflammation, ulcerations, and bleeding.
  • Patients with severe UC often exhibit a deficiency in factor XIII, crucial for clot stabilization and tissue repair.
  • The need for effective hemostasis and enhanced wound healing is critical in managing severe IBD.

Purpose of the Study:

  • To evaluate the efficacy of factor XIII concentrate in patients with therapy-resistant ulcerative colitis.
  • To assess the impact of factor XIII substitution on clinical symptoms, bleeding, and endoscopic scores.
  • To investigate factor XIII as a therapeutic agent for improving wound healing in severe intestinal inflammation.

Main Methods:

  • A prospective pilot study treated 12 patients with severe ulcerative colitis using factor XIII concentrate (1,250 U/d).

Related Experiment Videos

  • Clinical assessments included the colitis activity index (CAI) and endoscopic score (ES) by Rachmilewitz.
  • Two ongoing placebo-controlled multicenter trials are investigating different dosages of factor XIII concentrate in acute UC with bleeding and therapy-resistant UC.

    • Main Results:

    • Factor XIII concentrate substitution led to a significant reduction in stool frequency and cessation of hematochezia.
    • Highly significant declines were observed in both the colitis activity index (CAI) and endoscopic score (ES).
    • Initial case reports and pilot studies indicate favorable clinical outcomes, prompting larger trials.

    Conclusions:

    • Factor XIII concentrate shows significant promise in managing severe ulcerative colitis by controlling intestinal bleeding.
    • The therapy effectively promotes wound healing and reduces inflammatory markers in IBD patients.
    • Further placebo-controlled trials are underway to confirm the therapeutic benefits of factor XIII in ulcerative colitis.